Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 6/20 | 0.60 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.60 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | CD69 | Q07108 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.53 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.48 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.48 |
| ▸ | AMY2A | P04746 | 1/20 | 0.47 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29404773 | 0.95 | LGALS3 (0.62) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL15144324 | 0.95 | LGALS3 (0.62) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL29392475 | 0.95 | LGALS3 (0.62) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL30654785 | 0.95 | LGALS3 (0.62) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL31682925 | 0.95 | LGALS3 (0.62) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL31682915 | 0.95 | LGALS3 (0.62) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL31700517 | 0.94 | LGALS3 (0.59) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL31700504 | 0.94 | LGALS3 (0.59) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL31702077 | 0.94 | LGALS3 (0.59) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL31700297 | 0.94 | LGALS3 (0.59) | LGALS3LGALS8LGALS4MAPK1CD69 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12633372-B2 | Decoding approaches for protein identification | NAUTILUS SUBSIDIARY, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260004881-A1 | METHODS AND SYSTEMS FOR CHARACTERIZING PROTEINS | NAUTILUS SUBSIDIARY INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250391496-A1 | DECODING APPROACHES FOR PROTEIN IDENTIFICATION | NAUTILUS SUBSIDIARY INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250342902-A1 | DECODING APPROACHES FOR PROTEIN IDENTIFICATION | NAUTILUS SUBSIDIARY INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250292870-A1 | METHODS AND SYSTEMS FOR PROTEIN IDENTIFICATION | NAUTILUS SUBSIDIARY INC (US) | 2025-09-18 | — | — | US | disclosed |
| US-20250037789-A1 | DECODING APPROACHES FOR PROTEIN IDENTIFICATION | NAUTILUS SUBSIDIARY INC (US) | 2025-01-30 | — | — | US | disclosed |
| US-12148509-B2 | Decoding approaches for protein identification | NAUTILUS SUBSIDIARY, INC. (US) | 2024-11-19 | — | — | US | disclosed |
| EP-3701066-B1 | METHODS AND SYSTEMS FOR PROTEIN IDENTIFICATION | NAUTILUS SUBSIDIARY INC (US) | 2024-10-16 | — | — | EP | disclosed |
| EP-4372383-A2 | METHODS AND SYSTEMS FOR PROTEIN IDENTIFICATION | Nautilus Subsidiary, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| US-20230117795-A1 | DECODING APPROACHES FOR PROTEIN IDENTIFICATION | NAUTILUS BIOTECHNOLOGY, INC. | 2023-04-20 | — | — | US | disclosed |
| US-11282585-B2 | Decoding approaches for protein identification | NAUTILUS BIOTECHNOLOGY, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| US-20220068431-A1 | DECODING APPROACHES FOR PROTEIN IDENTIFICATION | NAUTILUS SUBSIDIARY, INC. | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260004881-A1 | METHODS AND SYSTEMS FOR CHARACTERIZING PROTEINS | PTMS, SRMS, CHAMP1 | LGALS3 1388/4885LGALS8 1371/4885LGALS4 1259/4885 |
| US-20250391496-A1 | DECODING APPROACHES FOR PROTEIN IDENTIFICATION | CHAMP1, PTMS, PSMG3 | LGALS3 1869/4885LGALS8 2109/4885LGALS4 1380/4885 |
| US-12633372-B2 | Decoding approaches for protein identification | HSPBP1, SRP19, SRP9 | LGALS3 2679/4885LGALS8 2408/4885LGALS4 1753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.